This website uses cookies to improve your experience. Learn more about cookies and how to manage them.

Dr David Sciberras

Dr David Sciberras

Name:

Dr David Sciberras FBPhS

Organisation:

UCB

Year elected:

2019

Affinity Group(s):

  • Drug Discovery, Development and Evaluation
  • Neuropharmacology

Primary professional setting:

Industry

Retired Pharmaceutical Industry professional with over 30 years experience in Early Development Scientific Innovation, Operations and Strategy across a wide range of therapeutic areas. A global thinker who has worked across Europe, in the US and in Japan. Qualified in Human Biology at University of Surrey (BSc) and went on to complete Masters Degree in Biopharmacy at Chelsea College, and a PhD in Clinical Pharmacology at University of London, based at the Royal Free Hospital. Spent 25 years at Merck, GE Healthcare and Amgen managing early phase drug development in a wide variety of therapeutic areas. Most recently at UCB with clinical pharmacology responsibility for early and some late phase drug development. Previous committee member of clinical section of British Pharmacological Society and Chair for Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI). Previous Chair of ABPI Experimental Medicines Group. Served on ABPI post-Tegenero Task Force. Now retired, but continue to provide limited voluntary advisory work in Clinical Pharmacology. Specialties: Clinical Pharmacology Nuclear imaging as biomarker Project Management Early Drug development in CNS